Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1987 Jul;24(1):37–42. doi: 10.1111/j.1365-2125.1987.tb03133.x

Studies of mefloquine bioavailability and kinetics using a stable isotope technique: a comparison of Thai patients with falciparum malaria and healthy Caucasian volunteers.

S Looareesuwan, N J White, D A Warrell, I Forgo, U G Dubach, U B Ranalder, D E Schwartz
PMCID: PMC1386277  PMID: 3304385

Abstract

1 A mefloquine hydrochloride tablet (250 mg base equivalent to 4.8 +/- 0.6 mg kg-1; mean +/- s.d.) and deuterium labelled mefloquine hydrochloride solution (250 mg base) were given to six adult male Thai patients with acute falciparum malaria and six healthy Swiss adult male volunteers (equivalent to 3.5 +/- 0.1 mg kg-1). 2 The relative bioavailability of the tablet formulation derived from comparison of the areas under the plasma concentration-time curves was similar in both groups; 87 +/- 11% and 89 +/- 10% (mean +/- s.d.). 3 The rate of drug absorption appeared to be similar in the two groups but peak plasma mefloquine concentrations were approximately three times higher in the Thai patients (1004 +/- 276 ng ml-1 for the tablet and 1085 +/- 280 ng ml-1 for the suspension) compared with the Swiss volunteers (319 +/- 73 ng ml-1 for the tablet, and 369 +/- 121 ng ml-1 for the suspension). 4 Estimates of the oral clearance CLpo of unlabelled mefloquine were significantly lower (17.5 +/- 4.4 ml h-1 kg-1) in the Thai patients compared with 28.8 +/- 3.5 ml h-1 kg-1 in the Swiss volunteers; P less than 0.05). Terminal elimination half-lives were significantly shorter in the patients (10.3 +/- 2.5 days) than in the volunteers (16.7 +/- 1.9 days; P less than 0.005). Differences of a similar magnitude were observed when comparing the pharmacokinetic parameters derived from the deuteromefloquine plasma concentrations. 5 Both genetic and disease related factors are likely to account for the large pharmacokinetic differences between the two groups.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
37

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chanthavanich P., Looareesuwan S., White N. J., Warrell D. A., Warrell M. J., DiGiovanni J. H., von Bredow J. Intragastric mefloquine is absorbed rapidly in patients with cerebral malaria. Am J Trop Med Hyg. 1985 Nov;34(6):1028–1036. doi: 10.4269/ajtmh.1985.34.1028. [DOI] [PubMed] [Google Scholar]
  2. Desjardins R. E., Pamplin C. L., 3rd, von Bredow J., Barry K. G., Canfield C. J. Kinetics of a new antimalarial, mefloquine. Clin Pharmacol Ther. 1979 Sep;26(3):372–379. doi: 10.1002/cpt1979263372. [DOI] [PubMed] [Google Scholar]
  3. Mu J. Y., Israili Z. H., Dayton P. G. Studies of the disposition and metabolism of mefloquine HCl (WR 142,490), a quinolinemethanol antimalarial, in the rat. Limited studies with an analog, WR 30,090. Drug Metab Dispos. 1975 May-Jun;3(3):198–210. [PubMed] [Google Scholar]
  4. Scheline R. R. Drug metabolism by intestinal microorganisms. J Pharm Sci. 1968 Dec;57(12):2021–2037. doi: 10.1002/jps.2600571202. [DOI] [PubMed] [Google Scholar]
  5. Schwartz D. E., Eckert G., Hartmann D., Weber B., Richard-Lenoble D., Ekue J. M., Gentilini M. Single dose kinetics of mefloquine in man. Plasma levels of the unchanged drug and of one of its metabolites. Chemotherapy. 1982;28(1):70–84. doi: 10.1159/000238062. [DOI] [PubMed] [Google Scholar]
  6. Schwartz D. E., Ranalder U. B. Highly sensitive and specific determination of mefloquine in biological fluids using gas chromatography mass spectrometry with selected ion monitoring. Biomed Mass Spectrom. 1981 Dec;8(12):589–592. doi: 10.1002/bms.1200081206. [DOI] [PubMed] [Google Scholar]
  7. Schwartz D. E., Weber W., Richard-Lenoble D., Gentilini M. Kinetic studies of mefloquine and of one of its metabolites, Ro 21-5104, in the dog and in man. Acta Trop. 1980 Sep;37(3):238–242. [PubMed] [Google Scholar]
  8. Silamut K., White N. J., Looareesuwan S., Warrell D. A. Binding of quinine to plasma proteins in falciparum malaria. Am J Trop Med Hyg. 1985 Jul;34(4):681–686. doi: 10.4269/ajtmh.1985.34.681. [DOI] [PubMed] [Google Scholar]
  9. Trenholme C. M., Williams R. L., Desjardins R. E., Frischer H., Carson P. E., Rieckmann K. H., Canfield C. J. Mefloquine (WR 142,490) in the treatment of human malaria. Science. 1975 Nov 21;190(4216):792–794. doi: 10.1126/science.1105787. [DOI] [PubMed] [Google Scholar]
  10. White N. J. Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacokinet. 1985 May-Jun;10(3):187–215. doi: 10.2165/00003088-198510030-00001. [DOI] [PubMed] [Google Scholar]
  11. White N. J., Looareesuwan S., Warrell D. A., Warrell M. J., Bunnag D., Harinasuta T. Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria. Am J Med. 1982 Oct;73(4):564–572. doi: 10.1016/0002-9343(82)90337-0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES